Literature DB >> 34024402

Rethinking Idiopathic Pulmonary Fibrosis.

Justin M Oldham1, Carlo Vancheri2.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a devastating disease for patients and their loved ones. Since initial efforts to characterize this disease in the 1960s, understanding of IPF has evolved considerably. Such evolution has continually challenged prior diagnostic and treatment paradigms, ushering in an era of higher confidence diagnoses with less invasive procedures and more effective treatments. This review details how research and clinical experience over the past half century have led to a rethinking of IPF. Here, the evolution in understanding of IPF pathogenesis, diagnostic evaluation and treatment approach is discussed.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Idiopathic interstitial pneumonia; Idiopathic pulmonary fibrosis; Interstitial lung disease; Usual interstitial pneumonia

Mesh:

Year:  2021        PMID: 34024402      PMCID: PMC9075032          DOI: 10.1016/j.ccm.2021.03.005

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   4.967


  96 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis.

Authors:  Timothy M Dempsey; Lindsey R Sangaralingham; Xiaoxi Yao; Darshak Sanghavi; Nilay D Shah; Andrew H Limper
Journal:  Am J Respir Crit Care Med       Date:  2019-07-15       Impact factor: 21.405

3.  Imaging Patterns Are Associated with Interstitial Lung Abnormality Progression and Mortality.

Authors:  Rachel K Putman; Gunnar Gudmundsson; Gisli Thor Axelsson; Tomoyuki Hida; Osamu Honda; Tetsuro Araki; Masahiro Yanagawa; Mizuki Nishino; Ezra R Miller; Gudny Eiriksdottir; Elías F Gudmundsson; Noriyuki Tomiyama; Hiroshi Honda; Ivan O Rosas; George R Washko; Michael H Cho; David A Schwartz; Vilmundur Gudnason; Hiroto Hatabu; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2019-07-15       Impact factor: 21.405

4.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Authors:  Paul W Noble; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Marilyn K Glassberg; David Kardatzke; Talmadge E King; Lisa Lancaster; Steven A Sahn; Javier Szwarcberg; Dominique Valeyre; Roland M du Bois
Journal:  Lancet       Date:  2011-05-13       Impact factor: 79.321

5.  Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.

Authors:  Luca Richeldi; Evans R Fernández Pérez; Ulrich Costabel; Carlo Albera; David J Lederer; Kevin R Flaherty; Neil Ettinger; Rafael Perez; Mary Beth Scholand; Jonathan Goldin; Kin-Hung Peony Yu; Thomas Neff; Seth Porter; Ming Zhong; Eduard Gorina; Elias Kouchakji; Ganesh Raghu
Journal:  Lancet Respir Med       Date:  2019-09-28       Impact factor: 30.700

6.  Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.

Authors:  Ganesh Raghu; Bernt van den Blink; Mark J Hamblin; A Whitney Brown; Jeffrey A Golden; Lawrence A Ho; Marlies S Wijsenbeek; Martina Vasakova; Alberto Pesci; Danielle E Antin-Ozerkis; Keith C Meyer; Michael Kreuter; Hugues Santin-Janin; Geert-Jan Mulder; Brian Bartholmai; Renu Gupta; Luca Richeldi
Journal:  JAMA       Date:  2018-06-12       Impact factor: 56.272

7.  Role of a Regional Multidisciplinary Conference in the Diagnosis of Interstitial Lung Disease.

Authors:  Japnam S Grewal; Julie Morisset; Jolene H Fisher; Andrew M Churg; Ana-Maria Bilawich; Jennifer Ellis; John C English; Cameron J Hague; Nasreen Khalil; Jonathon Leipsic; John Mayo; Nestor L Muller; Darra Murphy; Joanne L Wright; Christopher J Ryerson
Journal:  Ann Am Thorac Soc       Date:  2019-04

8.  Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis.

Authors:  Philip L Molyneaux; Saffron A G Willis-Owen; Michael J Cox; Phillip James; Steven Cowman; Michael Loebinger; Andrew Blanchard; Lindsay M Edwards; Carmel Stock; Cécile Daccord; Elisabetta A Renzoni; Athol U Wells; Miriam F Moffatt; William O C Cookson; Toby M Maher
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

9.  Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis.

Authors:  Prosenjit Dutta; Wendy Funston; Ian A Forrest; A John Simpson; Helen Mossop; Vicky Ryan; Rhys Jones; Rebecca Forbes; Shilpi Sen; Jeffrey Pearson; S Michael Griffin; Jaclyn A Smith; Christopher Ward
Journal:  Thorax       Date:  2019-01-04       Impact factor: 9.102

10.  Idiopathic pulmonary fibrosis and GERD: links and risks.

Authors:  Matteo Ghisa; Carla Marinelli; Vincenzo Savarino; Edoardo Savarino
Journal:  Ther Clin Risk Manag       Date:  2019-09-05       Impact factor: 2.423

View more
  1 in total

1.  Clinical efficacy and quality of life effect of acetylcysteine plus pirfenidone in patients with pulmonary fibrosis.

Authors:  Rong Zhang; Zhanshuai Song; Yan Guan; Juan Zhang; Jianfang Zou; Yingxin Sun; Hua Shao
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.